|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HORMONES AND SIGNALING
Department of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee
Submitted 19 January 2006 ; accepted in final form 9 June 2006
| ABSTRACT |
|---|
|
|
|---|
-induced apoptosis in IEC-6 cells. Rac1 is activated during TNF-
-induced apoptosis as judged by the level of GTP-Rac1, the level of microsomal membrane-associated Rac1, and lamellipodia formation. Although expression of constitutively active Rac1 does not increase apoptosis in the basal condition, inhibition of Rac1 either by NSC-23766 (Rac1 inhibitor) or expression of dominant negative Rac1 protects cells from TNF-
-induced apoptosis by inhibiting caspase-3, -8, and -9 activities. Inhibition of Rac1 before the administration of apoptotic stimuli significantly prevents TNF-
-induced activation of JNK1/2, the key proapoptotic regulator in IEC-6 cells. Inhibition of Rac1 does not modulate TNF-
-induced ERK1/2 and Akt activation. Inhibition of ERK1/2 and Akt activity by U-0126 and LY-294002, respectively, increased TNF-
-induced apoptosis. However, inhibition of Rac1 significantly decreased apoptosis in the presence of ERK1/2 and Akt inhibitors, similar to the effect observed with NSC-23766 alone in response to TNF-
. Thus, Rac1 inhibition protects cells independently of ERK1/2 and Akt activation during TNF-
-induced apoptosis. Although p38 MAPK is activated in response to TNF-
, inhibition of p38 MAPK did not decrease apoptosis. Rac1 inhibition did not alter p38 MAPK activity. Thus, these results indicate that Rac1 mediates apoptosis via JNK and plays a key role in proapoptotic pathways in intestinal epithelial cells.
IEC-6; NSC-23766; N17Rac1; caspases; c-Jun NH2-terminal kinase 1/2
Rac1 belongs to the Rho family of small GTPases and plays diverse roles in cellular function including ROS production, membrane ruffling, lamellipodia formation, the activity of transcriptional factors, cell cycle control, and the integrity of cell-cell adhesions (7, 23, 28, 29, 38, 45). Lores et al. (27) reported the first evidence showing that there is a high degree of thymus atrophy in mice expressing activated mutants of Rac protein, leading them to propose that Rac-dependent pathways might play an important role in apoptosis of T lymphocytes. This study resulted in many subsequent investigations of the role of Rac1 in apoptosis. It appears that whether Rac1 enhances or inhibits apoptosis is highly dependent on cellular context and/or the inducers of apoptosis (30, 53). The role of Rac1 in apoptosis of intestinal epithelial cells is unclear.
We have examined the function of polyamines (putrescine, spermine, and spermidine) in intestinal epithelial cells using a nontransformed line derived from rat crypt cells, the IEC-6 cell line (34). Depletion of polyamines with
-difluoromethylornithine (DFMO), which inhibits ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis, causes a significant increase in the resistance of cells to apoptosis (2, 37). We have also found that the activity of Rac1 is significantly inhibited in polyamine-depleted cells (36, 47). Given this background, the present study tested the hypothesis that Rac1 plays a role in TNF-
-induced apoptosis in intestinal epithelial cells. We examined whether Rac1 is activated during apoptosis and whether inactivation of Rac1 either by treatment with the specific chemical inhibitor NSC-23766 or the expression of a dominant negative (DN)-Rac1 mutant prevents apoptosis. We tested whether inactivation of Rac1 prevents apoptosis by inhibiting the activation of JNK, which is required for TNF-
-induced apoptosis (2, 3). Furthermore, we determined the role of TNF-
-induced ERK1/2, p38 MAPK, and Akt activation in Rac1-mediated apoptosis. Taken together, our results demonstrate that Rac1 mediates TNF-
-induced apoptosis via JNK irrespective of ERK1/2 and Akt activation and plays a key role in the proapoptotic pathway in intestinal epithelial cells.
| MATERIALS AND METHODS |
|---|
|
|
|---|
was obtained from Pharmingen (San Diego, CA). Rhodamine-phalloidin was purchased from Molecular Probes (Eugene, OR). NSC-23766 (Rac1 inhibitor), LY-294002 [phosphatidylinositol 3-kinase (PI3K)-Akt inhibitor], SP-600125 (JNK1/2 inhibitor), and SB-203580 (p38 MAPK inhibitor) were purchased from Calbiochem (La Jolla, CA). U-0126 (MEK inhibitor) was purchased from Promega (Madison, WI). The IEC-6 cell line (CRL 1592) was obtained from the American Type Culture Collection (Manassas, VA) at passage 13. The cell line was derived from the normal rat intestine and developed and characterized by Quaroni et al. (34). IEC-6 cells originate from intestinal crypt cells as judged by morphological and immunological criteria. They are nontumorigenic and retain the undifferentiated character of epithelial stem cells. Tests for mycoplasma were always negative. All chemicals were of the highest purity commercially available. Cell culture. IEC-6 cell stock was maintained in T-150 flasks in a humidified, 37°C incubator in an atmosphere of 90% air-10% CO2. The medium consisted of DMEM with 5% heat-inactivated FBS, 10 µg/ml insulin, and 50 µg/ml gentamicin sulfate. The stock was passaged weekly and fed three times per week, and passages 1522 were used. During the experimental setup, cells were trypsinized with 0.05% trypsin and 0.53 mM EDTA and counted using a Beckman Coulter counter (model Z1).
Transfection. IEC-6 cells were transfected with pMX-internal ribosome entry site (IRES)-green fluorescent protein (GFP)-V12-Rac1 [constitutively active (CA)], pMX-IRES-GFP-N17-Rac1 (DN), and pMX-IRES-GFP (vector). Stable clones were isolated and characterized as previously described (36).
Apoptosis studies.
Cells were plated (day 0) in T-75 flasks at a density of 6.25 x 104 cells/cm2 in DMEM-dialyzed FBS with triplicate samples for each group. Cells were fed on day 2. On day 3, the cell culture medium was removed and replaced with serum-free medium. On day 4, TNF-
(20 ng/ml) with CHX (25 µg/ml) was added to the serum-free medium for 3 h. After various treatments, images were photographed with a charge-coupled device camera using NIH Image software (version 1.58).
Caspase activity assay. The protocol used for the caspase assay was similar to that described previously (2). In brief, cells were harvested and washed with cold Dulbeccos phosphate-buffered saline (DPBS) buffer. The cell pellet was resuspended in ice-cold lysis buffer. After a 15-min incubation on ice, the lysate was centrifuged at 10,000 g at 4°C for 10 min. The supernatant was used for measurements of caspase-3, -8, and -9 activities. Each reaction (100 µl) contained 10 µl of cytosolic protein, 70 µl of assay buffer, and 20 µl of 2 mM Ac-DEVD-p-nitroanilide (pNA) for caspase-3, Ac-IETD-pNA for caspase-8, or Ac-LEHD-pNA for caspase-9 dissolved in assay buffer. The enzymatic reaction was carried out in 96-well plates at 37°C. Absorbance was read at 405 nm in a microplate reader. Protein was determined using the BCA method (Pierce, Rockford, IL), and caspase activity was expressed as picomoles of pNA released per milligram of protein per minute.
Quantitative DNA fragmentation ELISA. The protocol for quantitative DNA fragmentation ELISA was similar to that described previously (2). In brief, cells were harvested, lysed in lysis buffer for 30 min, and centrifuged at 200 g for 5 min to pellet nuclei. An aliquot of the supernatant was incubated with immunoreagents (anti-histone-biotin plus anti-DNA peroxidase-conjugated antibody) in 96-well streptavidin-coated plates on a shaker for 2 h. After samples were washed with incubation buffer, 100 µl of substrate buffer were added to each well, and samples were incubated for an additional 510 min. Absorbance was read at 405 nm in a microplate reader. Triplicates of the samples were used to quantify protein by the BCA method from Pierce. DNA fragmentation was expressed as absorbance units per milligram of protein per minute.
Cell migration assay. Cells were grown to confluence for 4 days in 35-mm plates, serum starved for 24 h, and then treated with or without 30 µM Rac1 inhibitor NSC-23766 3 h before the monolayer was wounded. Wounding was done by scratching with a gel-loading microtip as described previously (47). Immediately thereafter, scratches were photographed by a charge-coupled device camera using NIH Image software (version 1.58). The same fields were also photographed after 7 h to monitor the migration of cells.
Western blot analysis. Cells were first washed with ice-cold DPBS and lysed for 10 min in ice-cold extraction buffer. Lysates were centrifuged at 10,000 rpm for 10 min at 4°C. Supernatants from 10 to 50 µg protein were TCA precipitated, eluted in 1x SDS sample buffer for 5 min, and separated by 1015% SDS-PAGE. Proteins were transferred to Immunobilon-P membranes (Millipore, Bedford, MA) and probed with the indicated antibodies overnight at 4°C in TBS buffer containing 0.1% Tween 20 and 5% BSA or nonfat dry milk (blotting grade, Bio-Rad); all antibodies were diluted 1:1,000 with the exception of anti-caspase-3 at 1:1,500 and anti-actin at 1:5,000. Membranes were subsequently incubated with secondary antibody conjugated to horseradish peroxidase at room temperature for 1 h, and immunocomplexes were visualized by the ECL detection system. Quantitative analysis of the Western blots (densitometry) was carried out using NIH Image software. All data are expressed as means ± SE. All experiments were repeated three times.
Rac1 activation assay. The biological activity of Rac1 protein was analyzed using pulldown assays performed as described previously (36, 47). In brief, GST-p21-activated kinase fusion protein (GST-PAK; Rac1-binding domain of human PAK residues 51135) was prepared by lysing bacteria transformed with the GST-PAK plasmid construct in bacteria lysis buffer. The cell lysate was sonicated and clarified by centrifugation at 10,000 g for 15 min. The fusion protein was recovered by the addition of glutathione-agarose beads to the supernatant. The beads were washed three times in pulldown assay buffer and resuspended before the addition of cell lysates (150 µg). After being tumbled for 45 min at 4°C, beads were washed with pulldown assay buffer three times, and the amount of Rac1 protein bound to GST-PAK protein was analyzed by Western blot analysis. Proteins (20 µg) from each sample were resolved using SDS-PAGE to determine the level of total Rac1 protein.
Cell fractionation. The protocol used for the cell fractionation assay was similar to that described previously (47). Cells were grown for 4 days and serum starved for 24 h before being harvested. Cell monolayers were washed twice with DPBS, harvested in ice-cold cell lysis buffer [containing (in mM) 50 HEPES (pH 7.5), 50 NaCl, 1 MgCl2, 2 EDTA, and protease inhibitors], homogenized with a Dounce homogenizer using a type B pestle, and centrifuged at 1,500 g for 10 min. The resulting supernatant was centrifuged at 15,000 g for 10 min. The pellet was resuspended in cell lysis buffer. Equal amounts of protein were used for the detection of Rac1 using Western blot analysis.
Fluorescence detection of actin filaments. Cells were plated in 35-mm dishes, fixed with 3.7% formaldehyde, washed with PBS, permeabilized with 0.1% Triton X-100 for 5 min, blocked with 3% BSA for 20 min, and rinsed with 0.1% BSA for 20 min. Monolayers were stained with rhodamine-conjugated phalloidin for 1 h. Images were observed using a Nikon Diaphot inverted microscope with appropriate filters and processed with NIH Image.
Statistics. Data are expressed as means ± SE. All experiments were repeated three times (n = 3). Western blots are representative of three experiments. ANOVA with appropriate post hoc testing was used to determine the significance of the differences between the means of multiple treatments, and Student's t-test was performed for measuring the significance of the differences between the means of two treatments. P < 0.05 was regarded as statistically significant.
| RESULTS |
|---|
|
|
|---|
-mediated apoptotic signaling induces Rac1 activation.
Since GTP-bound Rac1, membrane-associated Rac1, and the formation of lamellipodia reflect the activation of Rac1, we analyzed these events in response to TNF-
. The level of GTP-bound Rac1 (active Rac1) was determined using a GST-PAK pulldown assay as previously described (36). As shown in Fig. 1A, TNF-
increased GTP-Rac1 levels transiently within 1 min (Fig. 1A, lane 2), which peaked between 10 and 30 min (Fig. 1A, lanes 4 and 5). To determine the levels of membrane-bound Rac1, a microsomal membrane fraction (heavy membrane) and whole cell extract were analyzed from untreated cells and those treated with TNF-
(Fig. 1B). TNF-
significantly increased membrane-associated Rac1 levels within 30 min and decreased them within 60 min without changes in the total amount of Rac1 protein. When Rac1 is activated, it interacts with downstream effectors and mediates cellular effects, such as lamellipodia formation. As shown in Fig. 1C, cells exposed to TNF-
for a short period of time (30 min) exhibited extensive lamellipodia accompanied by intense stress fiber formation. At a longer incubation time (60 min), these peripheral structures and stress fibers were gradually decreased. The concomitant activation of Rac1 during apoptosis suggests that Rac1 may modulate apoptotic signaling in these cells.
|
-induced apoptosis.
We examined the role of Rac1 in TNF-
-induced apoptosis by inhibiting its activation. We studied the effects of Rac1 inhibition on apoptosis by using a specific Rac1 inhibitor, NSC-23766. Gao et al. (14) recently identified this compound by structure-based virtual screening from the National Cancer Institute database. NSC-23766 fits the surface groove of Rac1 that is critical for Rac1-guanine nucleotide exchange factor (GEF) interaction. NSC-23766 has been tested in fibroblasts, human cancer cells (prostate cancer and breast cancer), myelin-forming cells, vascular smooth muscle cells, lung epithelial cells, and hematopoietic stem cells (6, 13, 14, 31, 41, 49). In these cell lines, NSC-23766 effectively blocks Rac1 activation and abolishes Rac1-mediated cellular events. However, its effectiveness in IEC-6 cells has not been tested. Therefore, we studied the effect of NSC-23766 on Rac1-mediated cellular events by examining wound healing, Rac1 activation, and lamelipodia formation. The results depicted in Fig. 2 demonstrate that pretreatment of the cells with 30 µM NSC-23766 for 3 h significantly inhibited migration (55%) compared with untreated cells. NSC-23766 significantly abolished the formation of lamellipodia compared with that in untreated cells exposed to TNF-
at different time points (Fig. 2C). In addition, NSC-23766 effectively inhibited both basal as well as TNF-
-induced Rac1 activation (Fig. 2D). The results shown in Fig. 2 clearly show that NSC-23766 effectively blocked Rac1-mediated cellular responses and confirmed the effectiveness of this compound for our study.
|
-induced apoptosis (2), we examined the effect of the inhibition of Rac1 on apoptosis. TNF-
caused detachment of cells, as evident by the appearance of refractory cells (arrows in Fig. 3Ab). Pretreatment of the cells with 30 µM NSC-23766 for 3 h followed by TNF-
exposure almost completely prevented the detachment, and cultures retained the morphological features of untreated monolayers (Fig. 3A, a and d). We further analyzed the effect of NSC-23766 on DNA fragmentation and capase-3 activation. TNF-
treatment significantly increased DNA fragmentation (4-fold) compared with untreated cells. Inhibition of Rac1 by NSC-23766 decreased TNF-
-induced DNA fragmentation by 50% (Fig. 3B). Caspase-3 activation as determined by a casapse-3 activity assay followed a pattern similar to DNA fragmentation (Fig. 3C). Because caspase-3 activation is the result of cleavage of procaspase-3, we determined the effect of NSC-23766 on procaspase-3 cleavage by Western blot analysis. Rac1 inhibition significantly decreased the formation of the caspase-3 active fragment (
17 kDa) compared with the control group in response to TNF-
(Fig. 3D). Furthermore, NSC-23766 alone had no effect on either DNA fragmentation or capase-3 activation in the basal condition. These results suggest that inhibition of Rac1 protects intestinal epithelial cells from apoptosis by inhibiting the activation of caspase-3 and subsequently decreasing DNA fragmentation.
|
-induced apoptosis.
We used CA-recombinant Rac1 and DN-recombinant Rac1 to validate our results from the Rac1 inhibitor study. IEC-6 cells were transfected with CA-Rac1, DN-Rac1, and vector DNA, and stably transfected clones were selected by limiting dilution (36). Selected clones transfected with CA-Rac1, DN-Rac1, and vector were characterized by determining the levels of GTP-Rac1. Cells expressing DN-Rac1 had significantly less GTP-Rac1 compared with vector- and CA-Rac1-expressing cells (Fig. 4A). As expected, CA-Rac1-expressing cells showed significantly higher levels of GTP-Rac1. In addition, recombinant Rac1-expressing cells had relatively more Rac1 protein compared with empty vector-transfected cells, indicating robust expression of these proteins. The above results confirmed the suitability of these clones for use in this study. Based on our inhibitor study, we predicted that DN-Rac1 expression should protect cells from apoptosis. CA-Rac1-transfected cells and vector-transfected cells showed relatively more refractory cells, indicating detachment (arrows in Fig. 4B, b and d) in response to the apoptotic stimulus, whereas untreated cells maintained a normal firmly adherent monolayer (Fig. 4B, a and c). TNF-
failed to induce detachment and morphological changes in DN-Rac1-transfected cells (Fig. 4Bf). These observations were further supported by DNA fragmentation (Fig. 4C). TNF-
induced a 3.5-fold increase in DNA fragmentation in vector-transfected cells compared with untreated cells. In CA-Rac1-transfected cells, TNF-
further increased DNA fragmentation, which was significantly higher compared with vector-transfected cells treated with TNF-
. As expected, expression of DN-Rac1 significantly decreased DNA fragmentation compared with both vector- and CA-Rac1-transfected cells.
|
. The activation of caspase-8 and -9 leads to activation of caspase-3 (2). DN-Rac1 significantly prevented the activation of caspase-3 compared with the levels seen in cells transfected with vector and CA-Rac1 (Fig. 5C).
|
-induced JNK activation.
Based on our previous study, which showed that TNF-
-induced JNK activation stimulates caspase-9 activation and, thereby, apoptosis in IEC-6 cells (2), it is highly possible that inhibition of caspase-3 and -9 by Rac1 inhibition is via altering the activation of JNK. Therefore, we determined the effect of Rac1 inhibition on JNK activation. During TNF-
-induced apoptosis, the phosphorylation of JNK1/2 increased in a time-dependent manner and then plateaued (Fig. 6A). Inhibition of Rac1 by NSC-23766 prevented TNF-
-induced JNK1/2 activation, as evident by the decreased phosphorylation of JNK1/2 (Fig. 6B). Interestingly, DN-Rac1 expression almost completely prevented TNF-
-induced JNK2 phosphorylation and significantly decreased JNK1 phosphorylation (Fig. 6C). JNK1/2 inhibition by a specific JNK inhibitor, SP-600125, or Rac1 inhibition by NSC-23766 significantly prevented TNF-
-induced DNA fragmentation compared with the control group (Fig. 6D). Taken together, these data clearly indicate that the inhibition of Rac1 protects cell from apoptosis via inhibiting TNF-
-induced JNK activation.
|
-induced ERK1/2 and Akt activation.
Previous studies (3, 4, 54) have shown that the MEK1/2-ERK1/2 and PI3K-Akt pathways are the two major prosurvival pathways in IEC-6 cells. Therefore, we examined whether inhibition of Rac1 attenuates apoptosis by modulating TNF-
-induced ERK1/2 and Akt activity. Inhibition of Rac1 by NSC-23766 had no effect on basal as well as TNF-
-induced ERK1/2 and Akt activation (Fig. 7A). In addition, TNF-
-induced activation of ERK1/2 or Akt was similar in CA-Rac1-, DN-Rac1-, and vector-transfected cells (Fig. 7B). Furthermore, prevention of TNF-
-induced ERK1/2 and Akt activation by U-0126 and LY-294002, respectively, significantly increased apoptosis as judged by DNA fragmentation. However, Rac1 inhibition by NSC-23766 significantly prevented TNF-
-induced DNA fragmentation in the presence and absence of these inhibitors. The inhibition of JNK1/2 by SP-600125 protected cells in a manner similar to NSC-23766 treatment in the presence and absence of U-0126 or LY-294002 (Fig. 8, A and B). These results indicate that inhibition of Rac1 mediates protection against TNF-
-induced apoptosis by inhibiting JNK1/2 independently of ERK1/2 and Akt activation.
|
|
-induced apoptosis.
Recent studies have shown that TNF-
-induced p38 MAPK activation requires Rac1 in human dermal microvascular endothelial cells (33) and that p38 MAPK is a proapoptotic molecule in myocytes (26). We determined whether TNF-
-induced Rac1 activation mediates apoptotic signaling via p38 MAPK in intestinal epithelial cells. As shown in Fig. 9A, TNF-
dramatically increased the phosphorylation of p38 MAPK, resulting in its activation, and Rac1 inhibition did not alter the response (Fig. 9A). In addition, treatment of cells with a p38 MAPK-specific inhibitor, SB-203580, did not attenuate TNF-
-induced DNA fragmentation compared with the control group (Fig. 9B). These data suggest that TNF-
-induced p38 MAPK activation does not mediate apoptosis and that Rac1-mediated effects on apoptosis are independent of p38 MAPK activation.
|
| DISCUSSION |
|---|
|
|
|---|
Switching between an inactive GDP-bound form and an active GTP-bound form, Rac1 plays a central role in signaling pathways related to cytoskeletal organization, cell migration, proliferation, and apoptosis (1, 5, 10, 18, 35, 46). In the resting stage, GDP-bound Rac1 resides in the cytosol as a complex with a Rho guanine nucleotide dissociation inhibitor (RhoGDI). After stimulation, Rac1 is released from RhoGDI and translocates to the membrane, where GTP is exchanged for GDP by GEFs such as Tiam1 (14).
Esteve et al. (12) showed that expression of DN-Rac1 protected the U937 leukemic cell line from TNF-
-induced apoptosis; however, Deshpande et al. (9) reported that DN-Rac1 increased the susceptibility of endothelial cells to TNF-
-induced apoptosis. These controversial results suggest that the role of Rac1 in TNF-
-induced apoptosis is highly dependent on cellular context. However, none of these studies examined the effect of TNF-
on Rac1 activity. Geijsen et al. (15) reported that TNF-
is not able to induce Rac activation in human neutrophils, suggesting that TNF-
does not activate Rac1 in all cell lines. Therefore, in this study, we first determined Rac1 activity during TNF-
-induced apoptosis in IEC-6 cells. We have shown that TNF-
alone does not induce apoptosis and that it requires the inhibition of protein synthesis (2). We used CHX with TNF-
to suppress the synthesis of short-lived members of the inhibitors of apoptosis group of proteins. Rac1 regulates the formation of lamellipodia in a large number of cell lines including IEC-6 cells (36). Wojciak-Stothard et al. (50) reported that TNF-
activated Rac1 as assessed by actin cytoskeleton changes. They demonstrated that quiescent human endothelial cells incubated with TNF-
for 530 min increased the formation of lamellipodia. With respect to IEC-6 cells, the levels of GTP-Rac1 began to increase within 1 min and achieved a peak at about 30 min in response to TNF-
(Fig. 1A). The increased level of membrane-associated Rac1 (Fig. 1B) following incubation with TNF-
for a short time (30 min) indicated that it does translocate from the cytosol to the membrane system for its activation. Exposure to TNF-
for 30 min led to increased formation of lamellipodia and stress fibers (Fig. 1C). Taken together, these results indicate that Rac1 is activated during TNF-
-induced apoptosis in IEC-6 cells.
Next, we established the proapoptotic role of Rac1 in TNF-
-induced apoptosis by using a Rac1-specific inhibitor and expression of DN-Rac1. DN-Rac1 (threonine to asparagine substitution at codon 17) lacks the ability to bind GTP and downstream effectors and inhibits Rac1 activity by competing with GEFs for endogenous Rac1. Inactivation of Rac1, either by treatment with Rac1 inhibitor or expression of the DN-Rac1 mutant, protected IEC-6 cells from apoptosis. Furthermore, expression of the CA-Rac1 mutant enhanced apoptosis, as indicated by the morphology, DNA fragmentation, and caspase-3 activity results (Figs. 35). These findings are consistent with results from others who have demonstrated that Rac1 is a proapoptotic molecule in response to different types of apoptotic stimuli in a variety of cell types. For example, overexpression of wide-type Rac1 protein accelerates apoptosis in chondrocytes during bone development (48), and the expression of DN-Rac1 protects H-Ras-transformed human breast epithelial cells from capsaicin-induced apoptosis (22). Moreover, in human hepatoma cells, overexpression of DN-Rac1 prevents growth factor deprivation-induced apoptosis (21). Eom et al. (11) also reported that overexpression of DN-Rac1 prevents UV-induced apoptosis in Rat-2 fibroblasts, and, recently, Ito et al. (20) demonstrated that
-adrenergic receptor stimulation induces apoptosis in rat ventricular myocytes in a Rac1-dependent manner. It is important to note that the CA-Rac1 mutant had no effect on apoptosis, caspase activation, and DNA fragmentation in the absence of apoptotic stimuli compared with DN-Rac1- and vector-transfected cells, suggesting that Rac1 by itself does not induce apoptosis. However, the rapid activation of Rac1 by TNF-
and enhancement of apoptosis in CA-Rac1-transfected cells indicate that Rac1 is a key modulator of receptor-mediated proapoptotic signaling pathways in intestinal epithelial cells.
As a "molecular switch," Rac1 has been implicated in the regulation of several signaling pathways related to apoptosis, including MAPK pathways (ERK1/2, JNK1/2, and p38 MAPK) and the PI3K-Akt pathway (30, 32, 52). The role of Rac1 in these signaling cascades is highly dependent on the cellular context and apoptotic stimulus. JNK is a key regulator of many cellular events, including epithelial cell shape changes during dorsal closure, proliferation, and apoptosis (25, 51). Our previous studies (2, 3) have indicated that JNK1/2 mediates TNF-
-induced apoptosis by promoting cytochrome c release, subsequently activating caspase-9, and sustained activation of ERK1/2 inhibits JNK activity in IEC-6 cells. In fact, whether Rac1 mediates JNK activation in response to apoptotic inducers including TNF-
is still debatable. Minden et al. (28) reported that Rac1 mediates JNK activity in response to EGF but not to TNF-
; Su et al. (43) also reported that Cdc42 rather than Rac1 mediates JNK activation during Fas ligand-related apoptosis in human leukemia HL-60 cells. Our current study indicated that inhibition of Rac1 was associated with a strong inhibition of the activation of JNK1/2 (Fig. 6, B and C) and nearly prevented the activation of caspase-9, whose activity is regulated by JNK1/2 during TNF-
-induced apoptosis in IEC-6 cells (Fig. 5B). In addition, TNF-
-induced ERK1/2, Akt, and p38 MAPK activities are independent of Rac1. Moreover, in the absence of TNF-
-induced ERK1/2 and Akt activation, the Rac1 inhibitor effectively prevented apoptosis similar to the effect of the JNK1/2 inhibitor. This indicates that Rac1 inhibition mediated the protection against TNF-
-induced apoptosis by inhibiting JNK1/2 independently of ERK1/2 and Akt (Figs. 79). These findings are consistent with the results of several studies (5, 16, 18, 42, 46) showing that Rac1 mediates the JNK apoptotic pathway in oligodendrocytes, thyroid cells, COS-1 cells, Jurkat cells, and human breast cancer cells.
In summary, our present work showed that TNF-
induced lamellipodia formation, increased levels of membrane-associated Rac1, and increased GTP-Rac1 levels, indicating that Rac1 is activated during the induction of apoptosis by TNF-
. Inactivation of Rac1 by treatment with either a specific inhibitor, NSC-23766, or expression of DN-Rac1 prevented TNF-
-induced apoptosis by blocking the activation of JNK. Inhibition of Rac1 protected cells from apoptosis in the absence of ERK1/2 or Akt activation, and Rac1 did not modulate the TNF-
-induced activation of p38 MAPK. Based on our present findings and earlier observations (summarized in Fig. 10), we conclude that Rac1 is an upstream positive modulator of TNF-
-induced JNK activation and plays an important role in the biological regulation of apoptosis in normal small intestinal epithelial cells. Future efforts will focus on elucidating the molecular mechanisms through which Rac1 regulates JNK-mediated apoptosis.
|
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
in IEC-6 cells. Am J Physiol Gastrointest Liver Physiol 285: G980G91, 2003.
-induced apoptosis in polyamine-depleted IEC-6 cells is mediated through the activation of ERK1/2. Am J Physiol Gastrointest Liver Physiol 286: G479G490, 2004.
-induced endothelial cell apoptosis: dual regulation by reactive oxygen species. FASEB J 14: 17051714, 2000.
B recruitment to the IL-8 promoter in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 290: L730L737, 2006.This article has been cited by other articles:
![]() |
J.-Y. Byun, M.-J. Kim, C.-H. Yoon, H. Cha, G. Yoon, and S.-J. Lee Oncogenic Ras Signals through Activation of Both Phosphoinositide 3-Kinase and Rac1 to Induce c-Jun NH2-Terminal Kinase-Mediated, Caspase-Independent Cell Death Mol. Cancer Res., September 1, 2009; 7(9): 1534 - 1542. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Matos and P. Jordan Increased Rac1b Expression Sustains Colorectal Tumor Cell Survival Mol. Cancer Res., July 1, 2008; 6(7): 1178 - 1184. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jin, R. M. Ray, and L. R. Johnson TNF-{alpha}/cycloheximide-induced apoptosis in intestinal epithelial cells requires Rac1-regulated reactive oxygen species Am J Physiol Gastrointest Liver Physiol, April 1, 2008; 294(4): G928 - G937. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Munoz-Alonso, L. Gonzalez-Santiago, N. Zarich, T. Martinez, E. Alvarez, J. M. Rojas, and A. Munoz Plitidepsin Has a Dual Effect Inhibiting Cell Cycle and Inducing Apoptosis via Rac1/c-Jun NH2-Terminal Kinase Activation in Human Melanoma Cells J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1093 - 1101. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Ray, H. Guo, M. Patel, S. Jin, S. Bhattacharya, and L. R. Johnson Role of myosin regulatory light chain and Rac1 in the migration of polyamine-depleted intestinal epithelial cells Am J Physiol Gastrointest Liver Physiol, April 1, 2007; 292(4): G983 - G995. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |